Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SNPS

Go back to Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
(NASDAQ: ARVN) Delayed: 9.24 -0.08 (0.86%)
Previous Close $9.32    52 Week High $ 
Open $9.27    52 Week Low $ 
Day High $9.43    P/E N/A 
Day Low $9.15    EPS $ 
Volume 527,002       

Pfizer Inc. (NYSE: PFE) Delayed: 28.02 -0.28 (0.99%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.18    P/E 16.98 
Day Low $27.83    EPS $1.65 
Volume 31,195,273       

Pfizer Inc. (NYSE: PFE) Delayed: 28.02 -0.28 (0.99%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.18    P/E 16.98 
Day Low $27.83    EPS $1.65 
Volume 31,195,273